Breast Surgery
SR | Partial breast irradiation for breast cancer
3 Feb, 2023 | 14:06h | UTCPartial Breast Irradiation for Breast Cancer – Agency for Healthcare Research and Quality
SR | Immediate breast reconstruction uptake in older women with primary breast cancer
1 Feb, 2023 | 13:04h | UTC
SR | Present and future of machine learning in breast surgery
1 Feb, 2023 | 13:03h | UTC
Commentary on Twitter
Open Access in BJS' November issue: Present and future of machine learning in breast surgery: systematic review https://t.co/mdE94BzOIt @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @paulo_sutt @robhinchliffe1 @young_bjs pic.twitter.com/XVPwgZaVIm
— BJS (@BJSurgery) November 20, 2022
Perspective | Endocrine treatment for 5 years or radiation for 5 days for patients with early breast cancer older than 65 years
26 Jan, 2023 | 12:04h | UTC
Commentary from the author on Twitter
🚨Hot off the press @JCO_ASCO: For decades we have been offering RT omission for early #bcsm patients, here we discuss how tides have changed and its time to omit hormonal therapy and treat with RT instead @TaghianAlphonse @MGHBreastOnc @LurieCancer
— George E. Naoum, MD, MMSCI (@George_E_Naoum) December 20, 2022
RCT | Breast-cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection vs. standard surgical treatment of axilla
24 Jan, 2023 | 14:15h | UTC
Commentary on Twitter
New & available #OpenAccess | Occurrence of breast-cancer–related #lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two-arm randomized clinical trial https://t.co/fXB7PfysCH @OncoAlert pic.twitter.com/wWNhC9BMvY
— ACS Journal Cancer (@JournalCancer) October 20, 2022
Cohort Study | Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
13 Jan, 2023 | 13:14h | UTC
Post-trial follow-up | Radiotherapy vs. surgery of the axilla after a positive sentinel node in breast cancer.
14 Dec, 2022 | 14:42h | UTCRadiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: ART Preferred Over ALND in Sentinel Node-Positive Early Breast Cancer – Cancer Therapy Advisor
Post-trial follow-up | Long-term outcomes of adjuvant denosumab in breast cancer.
22 Nov, 2022 | 13:14h | UTCLong-Term Outcomes of Adjuvant Denosumab in Breast Cancer – NEJM Evidence
Original Study: Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial – The Lancet (link to abstract – $ for full-text)
Cohort Study | Use of breast cancer risk factors may identify risk-adapted starting age of screening.
18 Nov, 2022 | 13:16h | UTCInvited Commentary: Risk-Based Approaches to Breast Cancer Screening in China – JAMA Network Open
Commentary on Twitter
https://twitter.com/JAMANetworkOpen/status/1590766235989708801
Phase 2 RCT | Non-hormonal drug reduces vasomotor symptoms in women taking oral adjuvant endocrine therapy after breast cancer.
15 Nov, 2022 | 12:58h | UTC
RCT | Comparison of acupuncture vs. sham acupuncture in the treatment of aromatase inhibitor–related joint pain.
15 Nov, 2022 | 12:47h | UTC
Commentary on Twitter
https://twitter.com/JAMANetworkOpen/status/1591113526222913538
RCT | Preoperative ultrasound-guided percutaneous cryoneurolysis for the treatment of pain after mastectomy.
10 Nov, 2022 | 13:41h | UTCInfographic: Tip of the Iceberg: The History of Cryoneurolysis – Anesthesiology
Single-arm P2 study | Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy.
2 Nov, 2022 | 14:23h | UTCEliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Elimination of Surgery Explored for Selected Breast Cancer Patients – HealthDay
Commentary on Twitter
Online first: #Eliminating breast #surgery for invasive #breastcancer in exceptional #responders to #neoadjuvant systemic #therapy: a multicentre, single-arm, phase 2 trial https://t.co/lxZa62zFZT pic.twitter.com/TS1dKqFhF1
— The Lancet Oncology (@TheLancetOncol) October 26, 2022
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
31 Oct, 2022 | 13:50h | UTC
Nonsurgical options for risk reduction of contralateral breast cancer in BRCA mutation carriers with early breast cancer.
31 Oct, 2022 | 13:41h | UTCNonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer – Journal of Clinical Oncology (free for a limited period)
Guideline | Reporting of surgically removed lymph nodes for breast tumors.
25 Oct, 2022 | 13:20h | UTC
Cohort Study | Systemic or vaginal hormone therapy after early breast cancer.
24 Oct, 2022 | 14:00h | UTCNews Release: Hormone replacement therapy doesn’t lead to breast cancer reoccurrence – Oxford University Press
Commentaries:
Hormone Replacement Therapy Won’t Raise Recurrence Rate for Breast Cancer Survivors – HealthDay
Recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.
14 Oct, 2022 | 14:12h | UTC
Cohort Study | Elevated C-reactive protein and subsequent patient-reported cognitive problems in older breast cancer survivors.
14 Oct, 2022 | 14:03h | UTC
Cohort Study | Association of long-term oncologic prognosis with minimal access breast surgery vs. conventional breast surgery.
13 Oct, 2022 | 13:38h | UTC
Commentary on Twitter
A single-center retrospective cohort study found that the long-term outcomes of minimal-access breast surgery are not significantly different from those of conventional #BreastSurgery in patients with stage 0-III #BreastCancer. https://t.co/SMQWCNSa4X
— JAMA Surgery (@JAMASurgery) October 6, 2022
RCT | Antibiotic prophylaxis vs. no prophylaxis in breast cancer surgery.
3 Oct, 2022 | 13:47h | UTCAntibiotic prophylaxis in breast cancer surgery (PAUS trial): randomised clinical double-blind parallel-group multicentre superiority trial – British Journal of Surgery (link to abstract – $ for full-text)
20-year follow-up of a RCT | Adjuvant Goserelin and Tamoxifen in premenopausal patients with breast cancer.
26 Sep, 2022 | 12:00h | UTCNews Release: Hormonal breast cancer treatment reduces long-term risk of recurrence – Karolinska Institutet
Commentary on Twitter
20-yr FU of the STOCKHOLM trial in pts with premenopausal #breastcancer reveals that those with genomic low-risk benefited most from tamoxifen & those with genomic high-risk from goserelin, with no benefit from combined goserelin-tamoxifen in either group: https://t.co/UDKo5huaFA
— NatureRevClinOncol (@NatRevClinOncol) August 4, 2022
RCT | Outpatient vs. inpatient preinduction cervical ripening using a synthetic osmotic dilator.
26 Sep, 2022 | 11:58h | UTC
M-A | Margin status and survival outcomes after breast cancer conservation surgery.
23 Sep, 2022 | 13:09h | UTCCommentary from the authors: Width of excision margins after breast conserving surgery for invasive breast cancer and distant recurrence and survival – The BMJ
News Release: Experts call for adequate tumour free margins in breast cancer surgery – BMJ Newsroom
RCT | Multiple doses of prophylactic intravenous antibiotics are no better than a single dose in implant-based breast reconstruction.
19 Sep, 2022 | 12:48h | UTC
Commentary on Twitter
Multiple-dose antibiotic prophylaxis was not superior to a single-dose regimen in preventing surgical site infection and implant removal after implant-based breast reconstruction in this RCT. https://t.co/p7GbNRMPfW #OAResarch
— JAMA Network Open (@JAMANetworkOpen) September 16, 2022